Nexaph
Finnrick has tested 242 samples from Nexaph across 10 products.
Take Action
Request Full Data Access to the Finnrick database of peptide tests.
Products
| Tests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Product | Rating | Count | Avg | Min | Max | Oldest | Most Recent | |
| TB-500 | 5 | 10 Jul 2025 | 30 Apr 2026 | |||||
| Cagrilintide | 12 | 14 Jun 2025 | 28 Apr 2026 | |||||
| CJC-1295 | 6 | 10 Jun 2025 | 6 Nov 2025 | |||||
| GHK-Cu | 9 | 4 Aug 2025 | 13 May 2026 | |||||
| Semaglutide | 15 | 11 Jun 2025 | 6 Mar 2026 | |||||
| BPC-157 | 16 | 29 Jun 2025 | 28 Apr 2026 | |||||
| Ipamorelin | 9 | 3 Jul 2025 | 16 Feb 2026 | |||||
| Retatrutide | 93 | 11 Jun 2025 | 25 May 2026 | |||||
| Tesamorelin | 26 | 29 Jun 2025 | 20 May 2026 | |||||
| Tirzepatide | 50 | 2 Jul 2025 | 11 May 2026 | |||||
The Nexaph samples tested by Finnrick were either acquired by Finnrick directly, or submitted by the public.
Customer Reviews
These indicators of customer satisfaction are based on reports submitted by the public through the Finnrick testing program, and are not verified.
Based on 49 overall satisfaction reports
People who submitted test requests to Finnrick gave Nexaph an average satisfaction rating of 4.6 out of 5 across 49 reports associated with samples received and tested by Finnrick.
Most recent Nexaph tests
Samples are tested in commercial labs
tests
products
Scores
First
Last
| Quantity | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Product | Certificate | Test Score | Label | Batch | Tested | Difference | Purity | Endotoxins | Batch ID | Container | Tested At | Sent By |
| 25 May 2026 | Retatrutide | View | 10mg | (no batch claim) | 11mg | +10.0% | 99.80% | n/a | NXP-3P1003122020 | No label / Black crimp / Blue cap | Lab G | Public | |
| 20 May 2026 | Tesamorelin | View | 10mg | (no batch claim) | 11.4mg | +14.0% | 99.90% | low | (no batch ID) | No label / Blue crimp / Clear Purple cap | Lab E | Public | |
| 19 May 2026 | Retatrutide | View | 6mg | (no batch claim) | 6.65mg | +10.8% | 99.90% | low | (no batch ID) | No label / Black crimp / Clear Blue cap | Lab E | Public | |
| 19 May 2026 | Retatrutide | View | 10mg | 11.2mg | 10.8mg | -3.7% | 99.90% | below LOQ | NXP-3P1004012026-02 | No label / Green crimp / Clear Purple cap | Lab E | Public | |
| 13 May 2026 | GHK-Cu | View | 50mg | (no batch claim) | 98.8mg | +97.6% | 99.90% | n/a | (no batch ID) | No Label / Black Crimp / Red Cap | Lab E | Public | |
| 11 May 2026 | Tirzepatide | View | 60mg | (no batch claim) | 62mg | +3.3% | 99.90% | below LOQ | (no batch ID) | No Label / Red Crimp / Green Cap | Lab E | Public | |
| 8 May 2026 | Retatrutide | View | 48mg | (no batch claim) | 46.6mg | -2.9% | 99.90% | n/a | NXP-3P4802242026 | No Label / Black Crimp / Clear Red Cap | Lab E | Public | |
About Nexaph Test Results From Finnrick
Nexaph is a peptide vendor with multiple products tracked in the independent testing dataset collected by Finnrick. This page compiles recent, batch-level test results across 10 products and 242 tests, including scores, test dates, batch IDs, and lab details. This enables you to compare quality over time, not just marketing claims.
Each tested sample receives a 0–10 score, with 10 being the best possible value. It is the total of three components: purity (0–4 points), quantity accuracy vs. the label or batch claim (0–4 points), and batch information quality (0–2 points).
When several test results are available for a product and vendor pair, you’ll also find a Finnrick Rating (A–E, where A is best and E is worst, X if an insufficient number of tests is available, or F in rare cases of documented and widespread fraud) and customer satisfaction reports with sub-scores that provide additional context. Use the table above to review purity, quantity accuracy, consistency between batches, and any notable outliers surfaced in Finnrick testing data.
Nexaph Testing Activity & Score Summary
In the past 30 days, Finnrick has published 11 new test results for Nexaph, and 33 in the past three months. The overall dataset includes 242 tested samples with an average score of 7.1/10 across all products.
Across 241 identity-tested samples, 98% were confirmed to contain the expected peptide (identity pass rate). Among those that passed, median purity was 99.7%. Approximately 89% of passing samples tested at or above 98% purity.
Here is a closer look at the most frequently tested products (top 3):
- Retatrutide (93 tests, 99% identity pass, median purity 99.8%) — Test scores are highly variable, ranging from 0.0 to 10.0 (average 7.4/10), suggesting significant batch-to-batch differences.
- Tirzepatide (50 tests, 100% identity pass, median purity 99.8%) — Test scores are highly variable, ranging from 3.0 to 10.0 (average 7.4/10), suggesting significant batch-to-batch differences.
- Tesamorelin (26 tests, 96% identity pass, median purity 99.3%) — Test scores are highly variable, ranging from 2.0 to 9.9 (average 7.0/10), suggesting significant batch-to-batch differences.